莎普爱思(603168.SH)：立他司特滴眼液III期临床试验完成首例受试者入组

Core Viewpoint - The company has completed the enrollment of the first subject in the Phase III clinical trial for Latanoprost eye drops, aimed at evaluating its efficacy and safety in treating dry eye in the Chinese population [1] Group 1 - The Phase III clinical trial is designed as a multi-center, randomized, double-blind, placebo-controlled study [1] - The trial's primary focus is to assess the effectiveness and safety of Latanoprost eye drops in the treatment of dry eye [1] - The first subject was enrolled on October 23, 2025 [1]